Shots:

• Novartis’ Kisqali + endocrine therapy has achieved 5 out of 5 scores on ESMO-MCBS- confirming substantial benefit for premenopausal women with HR+/HER2- aBC- based on OS benefit and improved QoL in the P-III MONALEESA-7 study
• Kisqali is also the only CDK4/6 inhibitor to receive a score of 4 out of 5 in combination with fulvestrant for 1L postmenopausal women with HR+/HER2- aBC based on the OS benefit and maintained QoL observed in P-III MONALEESA-3. Additionally- Kisqali + fulvestrant receive a score of 4 out of 5 in a 2L setting based on the MONALEEA-3 study
• New data presented at ESMO 2020 add to the substantial body of evidence further differentiating Kisqali as the only CDK 4/6 inhibitor that improves OS in two P- III trials- with consistent results across patient subgroups- and with QoL benefits. Kisqali in patients with endocrine resistance led to a 30% & 41% reduction in the risk of death in the MONALEESA-3 & -7 studies over standard endocrine therapy respectively

­ Ref: Novartis | Image: Novartis